Literature DB >> 27998976

Sialylation Controls Prion Fate in Vivo.

Saurabh Srivastava1,2, Elizaveta Katorcha1,2, Martin L Daus3, Peter Lasch3, Michael Beekes3, Ilia V Baskakov4,2.   

Abstract

Prions or PrPSc are proteinaceous infectious agents that consist of misfolded, self-replicating states of a sialoglycoprotein called the prion protein or PrPC The current work tests a new hypothesis that sialylation determines the fate of prions in an organism. To begin, we produced control PrPSc from PrPC using protein misfolding cyclic amplification with beads (PMCAb), and also generated PrPSc with reduced sialylation levels using the same method but with partially desialylated PrPC as a substrate (dsPMCAb). Syrian hamsters were inoculated intraperitoneally with brain-derived PrPSc or PrPSc produced in PMCAb or dsPMCAb and then monitored for disease. Animals inoculated with brain- or PMCAb-derived PrPSc developed prion disease, whereas administration of dsPMCAb-derived PrPSc with reduced sialylation did not cause prion disease. Animals inoculated with dsPMCAb-derived material were not subclinical carriers of scrapie, as no PrPSc was detected in brains or spleen of these animals by either Western blotting or after amplification by serial PMCAb. In subsequent experiments, trafficking of brain-, PMCAb-, and dsPMCAb-derived PrPSc to secondary lymphoid organs was monitored in wild type mice. PrPSc sialylation was found to be critical for effective trafficking of PrPSc to secondary lymphoid organs. By 6 hours after inoculation, brain- and PMCAb-derived PrPSc were found in spleen and lymph nodes, whereas dsPMCAb-derived PrPSc was found predominantly in liver. This study demonstrates that the outcome of prion transmission to a wild type host is determined by the sialylation status of the inoculated PrPSc Furthermore, this work suggests that the sialylation status of PrPSc plays an important role in prion lymphotropism.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Fourier transform IR (FTIR); N-linked glycans; N-linked glycosylation; cyclic amplification; prion; prion disease; protein misfolding; secondary lymphoid organs; sialic acid; sialylation; spleen

Mesh:

Substances:

Year:  2016        PMID: 27998976      PMCID: PMC5313106          DOI: 10.1074/jbc.M116.768010

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie.

Authors:  N A Mabbott; F Mackay; F Minns; M E Bruce
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

2.  Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions.

Authors:  Mikael Klingeborn; Brent Race; Kimberly D Meade-White; Bruce Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  Post-conversion sialylation of prions in lymphoid tissues.

Authors:  Saurabh Srivastava; Natallia Makarava; Elizaveta Katorcha; Regina Savtchenko; Reinhard Brossmer; Ilia V Baskakov
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

4.  Noninvasive imaging of dendrimer-type N-glycan clusters: in vivo dynamics dependence on oligosaccharide structure.

Authors:  Katsunori Tanaka; Eric R O Siwu; Kaori Minami; Koki Hasegawa; Satoshi Nozaki; Yousuke Kanayama; Koichi Koyama; Weihsu C Chen; James C Paulson; Yasuyoshi Watanabe; Koichi Fukase
Journal:  Angew Chem Int Ed Engl       Date:  2010-10-25       Impact factor: 15.336

5.  Synthetic mammalian prions.

Authors:  Giuseppe Legname; Ilia V Baskakov; Hoang-Oanh B Nguyen; Detlev Riesner; Fred E Cohen; Stephen J DeArmond; Stanley B Prusiner
Journal:  Science       Date:  2004-07-30       Impact factor: 47.728

6.  Infrared microspectroscopy detects protein misfolding cyclic amplification (PMCA)-induced conformational alterations in hamster scrapie progeny seeds.

Authors:  Martin L Daus; Katja Wagenführ; Achim Thomzig; Susann Boerner; Peter Hermann; Antje Hermelink; Michael Beekes; Peter Lasch
Journal:  J Biol Chem       Date:  2013-10-25       Impact factor: 5.157

Review 7.  The immunobiology of prion diseases.

Authors:  Adriano Aguzzi; Mario Nuvolone; Caihong Zhu
Journal:  Nat Rev Immunol       Date:  2013-11-05       Impact factor: 53.106

8.  Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response.

Authors:  Aaron F Carlin; Satoshi Uchiyama; Yung-Chi Chang; Amanda L Lewis; Victor Nizet; Ajit Varki
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

9.  Plasmacytoid dendritic cells sequester high prion titres at early stages of prion infection.

Authors:  Rocio Castro-Seoane; Holger Hummerich; Trevor Sweeting; M Howard Tattum; Jacqueline M Linehan; Mar Fernandez de Marco; Sebastian Brandner; John Collinge; Peter-Christian Klöhn
Journal:  PLoS Pathog       Date:  2012-02-16       Impact factor: 6.823

10.  Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.

Authors:  Elizaveta Katorcha; Natallia Makarava; Regina Savtchenko; Alessandra D'Azzo; Ilia V Baskakov
Journal:  PLoS Pathog       Date:  2014-09-11       Impact factor: 6.823

View more
  19 in total

1.  Analysis of Covalent Modifications of Amyloidogenic Proteins Using Two-Dimensional Electrophoresis: Prion Protein and Its Sialylation.

Authors:  Elizaveta Katorcha; Ilia V Baskakov
Journal:  Methods Mol Biol       Date:  2018

2.  Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease.

Authors:  Alejandro M Sevillano; Patricia Aguilar-Calvo; Timothy D Kurt; Jessica A Lawrence; Katrin Soldau; Thu H Nam; Taylor Schumann; Donald P Pizzo; Sofie Nyström; Biswa Choudhury; Hermann Altmeppen; Jeffrey D Esko; Markus Glatzel; K Peter R Nilsson; Christina J Sigurdson
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism.

Authors:  Natallia Makarava; Jennifer Chen-Yu Chang; Kara Molesworth; Ilia V Baskakov
Journal:  Neurobiol Dis       Date:  2020-01-27       Impact factor: 5.996

4.  Production of Artificially Doubly Glycosylated, 15N Labeled Prion Protein for NMR Studies Using a pH-Scanning Volatile Buffer System.

Authors:  Kevin M Schilling; Natalia C Ubilla-Rodriguez; Conner W Wells; Glenn L Millhauser
Journal:  J Org Chem       Date:  2019-11-20       Impact factor: 4.354

5.  Prion protein post-translational modifications modulate heparan sulfate binding and limit aggregate size in prion disease.

Authors:  Julia A Callender; Alejandro M Sevillano; Katrin Soldau; Timothy D Kurt; Taylor Schumann; Donald P Pizzo; Hermann Altmeppen; Markus Glatzel; Jeffrey D Esko; Christina J Sigurdson
Journal:  Neurobiol Dis       Date:  2020-05-24       Impact factor: 5.996

6.  Limited understanding of the functional diversity of N-linked glycans as a major gap of prion biology.

Authors:  Ilia V Baskakov
Journal:  Prion       Date:  2017-03-21       Impact factor: 3.931

Review 7.  Role of sialylation of N-linked glycans in prion pathogenesis.

Authors:  Natallia Makarava; Ilia V Baskakov
Journal:  Cell Tissue Res       Date:  2022-01-28       Impact factor: 4.051

8.  Analyses of N-linked glycans of PrPSc revealed predominantly 2,6-linked sialic acid residues.

Authors:  Elizaveta Katorcha; Ilia V Baskakov
Journal:  FEBS J       Date:  2017-09-30       Impact factor: 5.542

Review 9.  Cellular and Molecular Mechanisms of Prion Disease.

Authors:  Christina J Sigurdson; Jason C Bartz; Markus Glatzel
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 32.350

10.  Mineral licks as environmental reservoirs of chronic wasting disease prions.

Authors:  Ian H Plummer; Chad J Johnson; Alexandra R Chesney; Joel A Pedersen; Michael D Samuel
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.